CA2326552A1 - Nasal delivery system for inhaled nitric oxide - Google Patents
Nasal delivery system for inhaled nitric oxide Download PDFInfo
- Publication number
- CA2326552A1 CA2326552A1 CA002326552A CA2326552A CA2326552A1 CA 2326552 A1 CA2326552 A1 CA 2326552A1 CA 002326552 A CA002326552 A CA 002326552A CA 2326552 A CA2326552 A CA 2326552A CA 2326552 A1 CA2326552 A1 CA 2326552A1
- Authority
- CA
- Canada
- Prior art keywords
- port
- purge
- valve controller
- valve
- duration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
- A61M16/0666—Nasal cannulas or tubing
- A61M16/0672—Nasal cannula assemblies for oxygen therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0051—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0841—Joints or connectors for sampling
- A61M16/0858—Pressure sampling ports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
- A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
- A61M2016/0021—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with a proportional output signal, e.g. from a thermistor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
- A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
- A61M2016/0024—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with an on-off output signal, e.g. from a switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
Abstract
A device (60) for pulsed delivery of inhaled nitric oxide (NO) (68) to a spontaneously breathing patient. The device (60) delivers NO (68), e.g., through a nasal cannula (81), only during the inspiratory phase of the breathing cycle. The device (60) automatically executes a purge cycle when it is initially activated and when the time between breath-triggered NO pulses reaches a predetermined time limit. The purge cycle protects the patient from exposure to NO2 that otherwise would accumulate in the fluid lines (80) from reaction of static NO with oxygen in the air.
Description
NASAL DELIVERY SYSTEM FOR INHALED NITRIC OXIDE
Background of the Invention There is growing interest in the use of inhaled nitric oxide (NO) to treat various conditions characterized by pulmonary hypertension or hypoxemia.
Clinical use of inhaled NO began in the early 1990s. To date, inhaled NO has been administered primarily to critically ill, intubated, mechanically ventilated patients. Recently, it has become recognized that inhaled NO is also useful for treatment of spontaneously breathing patients such as cardiac surgery patients, organ transplant patients, and patients with pulmonary hypertension or sickle cell disease.
Systems for delivering inhaled NO to spontaneously breathing patients have been described (Wessel et al., 1994, Crit. Care. Med. 22:930). Inhaled NO has been delivered to spontaneously breathing patients through a nasal cannula (Yoshida et al., 1997, Am. J. Respir. Crit.
20~ Care Med. 155:526). In some cases, NO delivery through a nasal cannula has been pulsed delivery (Channick et al., 1996, Chest 109:1545).
In a normal human breathing pattern, about one third of the time consists of inspiration (inhalation), and about two thirds of the time consists of expiration (exhalation). Thus, in a continuous flow nasal cannula system, at least two thirds of the gas flowing from the source, e.g., a portable gas cylinder, is wasted. The basic concept of a pulsed dosage system is to deliver the therapeutic gas, e.g., oxygen or N0, only during the inspiratory phase of the breathing cycle.
By conserving gas, a pulsed dosage system reduces NO costs. It also increases the lifetime of an NO source (gas cylinder), or decreases cylinder size. The latter two considerations are particularly important in home-care systems and portable systems for ambulatory WO 99ld9921 PCT/US99/07183 patients. The mixture of NO and nitrogen administered from a nasal cannula system contains no moisture, and can cause discomfort from a drying effect on nasal membrane tissue. Thus, an additional benefit of a pulsed dosage system is reduced drying of nasal tissues. .This increases patient comfort and improves patient compliance.
NO is an unstable, diatomic, highly lipophilic free radical. NO reacts rapidly with molecular oxygen (OZ) to produce nitrogen dioxide (NOz), which is toxic at low levels. OSHA has set exposure limits for NOz at 5 ppm. Animal studies have shown altered surfactant hysteresis and produced alveolar cell hyperplasia, changes in the epithelium of the terminal bronchiole, and loss of cilia at inhaled NOZ concentrations as low as 2 ppm (Evans et al., 1972, Arch. Environ. Health 24:180;
Stephens et al., 1972, Arch. Environ. Health 24:160. In humans, 2.3 ppm NOZ has been shown to affect alveolar permeability (Rasmussen et al., 1992, Am. Rev. Respir.
Dis. 146:654). Increased airway reactivity in humans has been found at inhaled NO2 concentrations below 2 ppm (Bylin et al., 1988, Eur. Respir. J. 1:606; Morrow et al., 1992, Am. Rev. Respir. Dis. 145:291; Stephens et al . , supra) .
NO is typically manufactured from the reaction of sulfur dioxide with nitric acid (Body et al., 1995, J.
Cardiothorac. Vasc. Anesth. 9:748). Alternatively, it can be produced by reacting sodium nitrite and sulfuric acid (Young et al., 1996, Intensive Care Med. 22:77) or by the oxidation of ammonia over a platinum catalyst at high temperatures (Body et al., supra). Following its production, NO is mixed with nitrogen gas (NZ) to obtain the desired NO concentration. The NO/NZ mixture is placed into specially prepared, aluminum alloy cylinders. For medical applications, cylinders typically contain 400 to WO 99Id9921 PCT/US99/07183 800 ppm NO (Hess et al., supra). In an NO cylinder, the N02 concentration is normally less than 2~ of the NO
concentration-.
Summary of the Invention The invention features a device for pulsed delivery of inhaled nitric oxide to a spontaneously breathing patient. The device includes a valve having a first, a second, and a third port. The first port is selectively communicable with the second port or the third port. The device also includes a pressure sensor in fluid communication with the third port. A valve controller is responsive to the pressure sensor. The valve controller selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined pulse time. A monitor operably linked to the valve controller measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time, and then signals the valve controller to reconnect the first port to the third port. The monitor and automatic purge cycle advantageously protect the patient from exposure to NOZ
Which otherwise would accumulate in fluid lines during an extended period in which NO/nitrogen does not flow.
The device can include a means for inactivation when not in use, e.g., an on/off switch, and a means for triggering the valve controller to selectively connect the first port to the second port for a predetermined purge time whenever the device undergoes start-up following a state of inactivation. This feature advantageously protects the patient from exposure to NOz accumulated in the fluid lines, when the patient initiates use of the device after the device has been turned off.
The purge time is preselected to provide a purge volume of 1 to 5 dead space volumes, preferably from 2 to 4 dead space volumes, and most preferably about 3 dead space volumes.
The device can also include an alarm operably connected to the monitor. The alarm provides a visual or audible indication whenever the duration of connection between the first port and third port exceeds a predetermined flow-off time, i.e., when the pressure sensor fails to detect inspiration by the patient. The alarm alerts the patient and/or a caretaker that pulsatile delivery of NO has not occurred for a preselected time, e.g., 15 seconds, 30 seconds, or 45 seconds.
The device can also include a purge cycle indicator that provides a continuous visual or audible indication that begins whenever a purge cycle begins, continues throughout the purge cycle, and ends when the purge cycle ends. This indicator warns the patient or caretaker when to wait for NOZ to be purged from the system, and when it is safe to begin use of the device.
The invention also includes a dual delivery device for separate, concurrent, pulsed delivery of inhaled nitric oxide and pulsed delivery of oxygen through a split nasal cannula to a spontaneously breathing patient.
NO is delivered through one side of the split cannula, and oxygen is delivered independently through the other side of the split cannula.
The NO portion of the dual delivery device includes a valve having a first, a second, and a third port. The first port is selectively communicable with the second port or the third port. The NO portion of the device also includes a pressure sensor in fluid communication with the third port, and a valve controller responsive to the pressure sensor. The valve controller selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined NO pulse time. A
monitor operably linked to the valve controller measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time. The monitor then signals the valve controller to reconnect the first port to the third port.
The dual delivery device also includes a pulsed oxygen delivery system that includes a valve having a first, a second, and a third port. The first port is selectively communicable with the second port or the third port. The oxygen portion of the dual delivery device also includes a pressure sensor in fluid communication with the third port, and a valve controller responsive to the pressure sensor. The valve controller selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined oxygen pulse time.
The oxygen portion of the dual delivery device can also include a monitor operably linked to the valve controller. The monitor measures the duration of WO 99Ia9921 PCT/US99/07183 connection between the first port and third port; and an alarm indicator operably linked to the monitor so that an oxygen pulse "fail" alarm indication results when the monitor detects a duration of connection between the first port and third port equal to, or greater than a predetermined time limit. This feature alerts the patient or caregiver that the desired pulsed oxygen delivery is not taking place on the oxygen side of the system.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present application, including definitions will control. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference.
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
Brief Description of the DrawincLs FIG. 1 is a block diagram showing the arrangement of a valve, valve controller, pressure sensor, monitor, and alarm, in a device according to the invention.
FIG. 2 is a schematic diagram of a purge timing circuit useful in a device according to the invention.
WO 99149921 PCTlUS99/07183 FIG. 3 is a schematic diagram of purge delay circuitry useful in a device according to the invention.
FIG. 4 is a schematic diagram of alarm circuitry useful in a'device according to the invention.
FIG. 5 is a schematic representation of a device for separate, concurrent, pulsed delivery of inhaled NO
through a split cannula system to a spontaneously breathing patient.
Detailed Description An embodiment of the invention represented schematically in FIG. 1 includes a three-way, two position valve 10, such as a solenoid-actuated, spool valve. Valve 10 has ports 10a, lOb, and lOc in its bore.
Port 10a is connected to a line (not shown) so as to be in fluid communication with a nasal cannula (not shown).
Port lOc is connected to a line (not shown) so as to be in fluid communication with a source of NO gas (not shown). Port lOb is in fluid communication with a pressure sensor 20 by means of fluid line 15. The position of the valve 10 is electrically controlled by a valve controller 30.
When a patient wearing the nasal cannula inhales during normal breathing, gas pressure in the cannula drops below ambient air pressure. This negative pressure is transmitted from port 10a through the valve and through fluid line 15 to the pressure sensor 20. Upon sensing a negative pressure event, the pressure sensor 20 causes the valve controller 30 to selectively connect port l0a to port lOc. In this "flow-on" position, the valve 10 allows NO gas to flow into the nasal cannula, from which the NO gas is delivered into one, or both, of the patient's nostrils.
The valve controller 30 maintains the valve in the "flow-on" position for a predetermined "pulse" time. At _ g _ the end of the pulse time, the valve controller 30 returns the valve to the "flow-off" position (port IOa connected to port lOb), thereby completing a pulsed dose cycle. With the valve returned to the "flow-off"
position, the device is ready for detection of the patient's next breath, and repetition of the pulsed dose cycle.
The pressure sensor 20 includes suitable means for sensing a negative fluidic pressure applied along line 15 and for generating an electrical signal upon sensing a negative pressure event. Suitable means for sensing a negative pressure associated with normal breathing include a pressure-to-electric (P/E) switch, which can be used in conjunction with a fluid amplifier. In some embodiments, the pressure sensor 20 includes a pressure transducer, e.g., a solid state-type, a capacitance-type, or an diaphragm-type (electromechanical) transducer.
Suitable valves, pressure sensing devices, valve controlling devices, and their integrated use for pulsatile delivery of a gas {oxygen) to a patient are described in detail in Durkan et al., U.S. Patent No.
4,462,398. Prior art teachings with regard to devices for pulsatile delivery of oxygen through a nasal cannula are generally applicable in the present invention, except for possible material compatibility considerations.
Materials compatible with NO include Teflon~, silicone, nickel, aluminum, and stainless steel. In addition, high pressure rubber hoses and plastic tubing commonly used for oxygen delivery are suitable for use with the NO
concentrations used clinically.
The monitor 50 measures the flow-off time, i.e., the time during which port l0a of the valve 10 is connected to port lOb of the valve 10. When the valve 10 remains in the flow-off position for a predetermined time limit, the monitor 50 electrically signals the valve WO 99Jd9921 PCT/US99/07183 controller 30 to switch the valve 10 to the flow-on position (i.e., port 10a connected to port lOc) for a predetermined "purge" time. At the end of the predetermined purge time, the valve controller 30 switches the valve 10 back to the flow-off position, thus completing a purge cycle.
As long as the mixture of NO and nitrogen is flowing from the source and through the system, air is prevented from backing up into the nasal cannula. During the flow-off time, air begins mixing with residual NO in the nasal cannula. Oxygen in the air spontaneously reacts with the residual NO in the lines to produce NOZ, which is toxic. Thus, when the flow-off time reaches a predetermined limit, the monitor 50 electrically signals the valve controller 30 to switch the valve 10 to the flow-on position. This causes a predetermined amount of gaseous NO/nitrogen ("purge volume") to flow from the source (gas cylinder) and through the system, thereby purging accumulated NOZ from the valve 10, the cannula, and any lines between the valve 10 and the cannula.
Preferably, the purge volume is between 1 and 5 dead space volumes. More preferably, the purge volume is between 2 and 4 dead space volumes, with about 3 dead space volumes being most preferred. The dead space volume is the total volume in the fluid path between port lOb and the ends of the nasal prongs, which terminate the nasal cannula. The dead space volume can be calculated readily from the internal dimensions of the components of the fluid pathway. The flow rate of the gaseous mixture of NO/nitrogen will be adjustable and known in terms of volume per unit time. Using this information, the desired purge volume can be converted to the predetermined purge time incorporated in a purge cycle.
In the embodiment represented by FIG. 1, the monitor measures the flow-off time indirectly, by means WO 99/d9921 PCT/US99/07183 of electrical connections with the valve controller 30.
In other embodiments, the monitor measures the duration indirectly, by means of electrical signals from the pressure sensor 20. In yet other embodiments, the monitor measures the duration directly, by means of a connection (electrical or mechanical) with the valve 10.
In the embodiment depicted in FIG. 1, the valve controller 30 controls the position of the valve 10. The valve controller 30 provides an input to the monitor 50 that indicates whether the valve 10 is in the "flow-off"
position lOb (logical 1 or high voltage) or the "flow-on"
position lOc (logical 0 or low voltage). The monitor 50 can employ a variety of methods to control the valve controller 30 and the alarm 40. These methods include microprocessor circuitry or TTL compatible circuitry. As an example, a monitor 50 that employs a combination of FETs and analog devices is described.
Referring to FIG. 2, a purge timing circuit has an input Vin that represents the flow-off and flow-on positions of the valve 10. When the valve is in the flow-off position, Vin transitions to a high voltage.
Previous to the transition, the P-channel FETs (Q2, Q3, and Q5) were conductive, i.e., on, and the N-channel FET
Q1 was not conductive, i.e., off. When the valve position changes and Vin transitions from a low to a high voltage, the P-channel FETs are turned off and the N-channel FET Q1 is turned on. Thus, the circuit is no longer clamped to ground. Current begins to flow from Vdd through Q1 and through the RC circuit formed by R1 and C1. After a time delay defined by the RC time constant, the voltage at the gate of Q4 is sufficient to turn Q4 on. At this time, current flows from Vdd through Q4 and Vpurge goes high.
When V purge is high, the valve controller 30 changes the position of the valve 10 to the flow-on position and purges the system. Consequently, the value of Vin transitions back to "0". The P-channel FETs Q2, Q3 and Q5 are on and the N-channel FET Q1 is off.
Because the circuit is clamped to ground, the N-channel FET Q4 also is off and Vpurge returns to a "0".
The parameters of the purge timing circuitry are chosen to produce a transition at Vpurge after a predetermined time delay. For example, vdd is 5 V; the threshold voltages of Q1, Q2, Q3, and Q5 are relatively low, e.g., 1 V; the threshold voltage of Q4 is higher, e.g., 4.5 V; and the RC time constant of R1 and C1 is designed to be approximately 15 seconds. Therefore, Q4 will turn on after approximately 15 seconds because the threshold voltage is chosen to be 90~ of the supply voltage Vdd. If Vin is not high for 15 seconds or more, the P-channel FETs Q2, Q3, and Q5 reset the circuit by clamping the circuit to ground and discharging the capacitor.
Referring to the purge delay circuitry of FIG. 3, when Vpurge is high, the signal Vwait goes high and provides a signal to the valve controller that the system should purge NO in the lines. The valve 10 moves to the "flow-on" position and NO flows through the system. The valve 10 (FIG. 1) remains in the flow-on position until Vwait, a pulse of predetermined duration, transitions back to a low state. The purge is also initiated on system startup by a power-on pulse which is the second input in the three input OR gate. The power on pulse is generated only once by a trigger device, known in the prior art, and ensures that fresh NO is available at start up.
The purge delay circuitry has an RC delay formed by R2 and C2 similar to the purge timing circuitry. The RC delay is designed to extend the Vwait pulse for the period required to purge 1 to 5 dead volumes of N0.
WO 99Id9921 PCT/US99/07183 When Vpurge goes high, P-channel FETs Q7, Q8 and Q10 turn off and N-channel FET Q8 turns on. C2 begins to charge, and the drain of Q6 is connected to the gate of Q11. Therefore, N-channel FET Q9 is off; P-channel FET
Q12 is on; and the combination of Q11 and Q12 conducts current to the gate of N-channel FET Q13. Because P-channel FET Q14 is off, the voltage at Vwait transitions to Vdd. Thus, the output transitions high almost instantaneously.
Vwait is fed back into the three input OR gate and holds the input to the gates of Q6 and Q7 at a high level. Thus, when valve 10 moves to the flow-on position and Vpurge transitions back to low, Vwait will remain high, and the RC circuit will continue to charge capacitor C2. When the capacitor is charged after a period defined by the RC delay of the circuit, Q9 turns on, and the gate of Q12 is high. Thus, Q12, a P-channel FET, stops conducting and the gates of Q13 and Q14 are low. When the gates are at a low voltage, Q13 is off and Q14 clamps Vwait to ground. When the pulse Vwait terminates, the valve controller 30 changes the valve position, and the purge timing circuitry again begins to monitor for pressure changes.
Similar to the purge timing circuitry, Q6, Q7, Q8 and Q10 of the purge wait circuitry have relatively low threshold voltages, e.g., 1 V, and Q9 has a threshold voltage approximately 90~ of Vdd. Resistor R3 is a small resistor that ensures the full value of Vdd is applied to the gates of Q13 and Q14.
The monitor 50 is electrically connected to an alarm 40, which indicates when the predetermined flow-off time limit has been reached. A flow-off time in excess of the predetermined limit can result from various causes. For example, the nasal cannula may become dislodged from the patient's nostrils when the patient WO 99/d9921 PCT/US99/07183 moves his/her head while asleep. The alarm 40 includes a visual indication such as a flashing light, or an audible indication such as a beeping tone, or both. The alarm alerts the patient or caretaker(s), so that the condition causing cessation of pulsed NO delivery can be promptly corrected. Prompt correction is particularly important where an NO rebound effect is a concern. NO rebound effects include pulmonary hypertension, hypoxemia, and heart failure.
Several alarm configurations can be constructed from the circuitry in FIGS. 2-4. For example, the output Vpurge can be connected to a "Wait" light (FIG. 5) to indicate the system is purging. The complement of Vwait can be connected to a "Ready" light to indicate the system has completed purging. Referring to FIG. 4, the reset logic is used for an embodiment of the invention where the patient, or other person, must reset a "Fail"
(FIG. 5) light when a purge is performed. The output Vpurge is the input into an OR gate OR-1. The output of OR-1 is fed back as the second input to maintain the output Vfail in a high state. Vfail is connected to a "Fail" light (not shown) which is illuminated when Vfail is high. N-channel FET Q16 resets OR-1 when AND-1 provides a low output to the gate of Q16. With Vpurge low, Q16 causes the second input to OR-1 to go low, causing Vfail to go low.
However, Vfail does not transition to the low state until the purge cycle is complete (Vwait is low) and the patient resets the fail light (Reset = on).
These signals are ANDed in AND-1 to detect this state.
The output of AND-1 is used to reset the feedback of OR-1 and OR-2.
Because Vpurge will transition to a low state before Vwait, Vfail will transition low when the feed back loop is clamped to ground.
OR-2 has a feedback loop to ensure that, if the fail reset is pressed before the purge cycle is complete, the fail light will extinguish when Vwait transitions to a low state. With AND-1 at a low state, N-channel FET
Q15 will be off, which keeps OR-2 high. AND-1 will remain at a logic low state until Vwait goes low. When AND-1 goes high, the OR-2 and OR-1 gates are reset. The resistors R4 and R5 are small resistors that prevent the clamping FETs Q15 and Q16 from shorting Vdd to ground and that ensure the input is clamped to ground quickly. The circuitry does not generate a fail light on start up when the system initially purges, but does generate a wait light on start up based on Vwait.
Preferred embodiments of the invention include a purge cycle indicator, which is activated at the beginning of every purge cycle and deactivated at the end of the purge cycle. The indicator can be visual, audible, or both. The purge indicator can be a readily visible, color-coded light or a liquid crystal display.
Suitable markings for a light that illuminates during the purge cycle include "WAIT" and "PURGING." Suitable purge-cycle messages for a liquid crystal display include "WAIT" and "PURGING." Upon completion of the purge cycle, suitable liquid crystal display messages include "OK" and "READY."
Preferred embodiments of the invention include automatic purging each time the device is connected to a power source after having been disconnected. Connection and disconnection can be by means of an ordinary on/off switch, by battery insertion and removal, or by plugging and unplugging a power cord. Preferably, a purge cycle (discussed above) is triggered whenever an electrical circuit in the valve controller 30 energized after having been de-energized.
Typically, the source of gaseous NO/nitrogen used for inhaled NO therapy is a high pressure cylinder, which requires an appropriate (pin index safety system or diameter index safety system) pressure regulator. A
device according to this invention can be incorporated into an integrated unit that includes a pressure regulator. Alternatively, the device can be a separate unit connected between a conventional NO pressure regulator and a conventional nasal cannula.
The device of this invention can be used in conjunction with a conventional flow regulator.
Referring to Fig. 1, the flow regulator (not shown) is inserted at a point in the fluid path between a pressure regulator (not shown) and port 10c on the valve 10.
Referring to Fig. 1, the NO dosage delivered to the patient by the device of this invention can be adjusted in any of at least three ways. One way of adjusting the dosage is varying the pulse time, i.e., the time that the valve 10 is in the flow-on position during a pulsed dose cycle, wherein the flow rate remains constant. A second way of adjusting the dosage is varying NO/nitrogen flow rate, wherein the pulse time remains constant. Flow rate can be adjusted by any suitable means, e.g., a manual valve or a proportioning solenoid. A third way of adjusting the dosage is programming the valve controller 30 to move the valve 10 to the flow-on position on a breath-dependent schedule, e.g., every second breath, every third breath, or every fourth breath.
In therapeutic use of a device of this invention, the desired NO dosage will be determined in accordance with accepted medical practice, depending on the condition being treated and the status of the patient.
Regardless of the means for adjusting NO dosage, the NO/nitrogen flow rate during the flow-on phase of the WO 99Id9921 PCT/US99/07183 pulsed dose cycle is preferably from 0.25 to 8 liters per minute, and more preferably from 1 to 4 liters per minute.
The following equations are useful for obtaining the desired NO dosage when delivering inhaled NO through a nasal cannula system:
[N03 - (NO flow x source ppm) /total flow [NO] in cannula = (desired NO dose x mean inspiratory flow)/cannula flow For additional guidance concerning calculations and considerations for inhaled NO delivery systems, see Hess et al., 1997, Resp. Care Clinics of North America 3:371.
FIG. 5 illustrates selected features of a device 60 for separate, concurrent, pulsed delivery of inhaled nitric oxide and pulsed delivery of oxygen through a split nasal cannula 80, 81. to a spontaneously breathing patient.
A mixture of NO/nitric oxide flows from an NO
source cylinder 68 through a cylinder shutoff valve 65, a pressure regulator 66, and fluid line 69, into the device 60. The NO control panel 60a includes an NO main power switch 67 and a knob 61 for adjusting NO dosage to the desired level. The NO control panel 60a also includes a purge cycle indicator light 64, an indicator light that signals when it is safe for the patient to begin using the device 63, and an alarm indicator light 62.
Oxygen flows from an oxygen source cylinder 78 through a cylinder shutoff valve 75, a pressure regulator 76, and fluid line 79, into the device 60. The oxygen control panel 60b includes an oxygen main power switch 77 and a knob 71 for adjusting oxygen dosage to the desired level. The oxygen control panel 60b includes a first light 73, which indicates that pulsed oxygen delivery is proceeding without the oxygen flow-off time exceeding the predetermined limit. The oxygen control panel 60b also includes a second light 72, which indicates that pulsed WO 99149921 . PCT/US99/07183 oxygen delivery has failed to occur without exceeding the predetermined flow-off time.
Other embodiments are within the following claims.
Background of the Invention There is growing interest in the use of inhaled nitric oxide (NO) to treat various conditions characterized by pulmonary hypertension or hypoxemia.
Clinical use of inhaled NO began in the early 1990s. To date, inhaled NO has been administered primarily to critically ill, intubated, mechanically ventilated patients. Recently, it has become recognized that inhaled NO is also useful for treatment of spontaneously breathing patients such as cardiac surgery patients, organ transplant patients, and patients with pulmonary hypertension or sickle cell disease.
Systems for delivering inhaled NO to spontaneously breathing patients have been described (Wessel et al., 1994, Crit. Care. Med. 22:930). Inhaled NO has been delivered to spontaneously breathing patients through a nasal cannula (Yoshida et al., 1997, Am. J. Respir. Crit.
20~ Care Med. 155:526). In some cases, NO delivery through a nasal cannula has been pulsed delivery (Channick et al., 1996, Chest 109:1545).
In a normal human breathing pattern, about one third of the time consists of inspiration (inhalation), and about two thirds of the time consists of expiration (exhalation). Thus, in a continuous flow nasal cannula system, at least two thirds of the gas flowing from the source, e.g., a portable gas cylinder, is wasted. The basic concept of a pulsed dosage system is to deliver the therapeutic gas, e.g., oxygen or N0, only during the inspiratory phase of the breathing cycle.
By conserving gas, a pulsed dosage system reduces NO costs. It also increases the lifetime of an NO source (gas cylinder), or decreases cylinder size. The latter two considerations are particularly important in home-care systems and portable systems for ambulatory WO 99ld9921 PCT/US99/07183 patients. The mixture of NO and nitrogen administered from a nasal cannula system contains no moisture, and can cause discomfort from a drying effect on nasal membrane tissue. Thus, an additional benefit of a pulsed dosage system is reduced drying of nasal tissues. .This increases patient comfort and improves patient compliance.
NO is an unstable, diatomic, highly lipophilic free radical. NO reacts rapidly with molecular oxygen (OZ) to produce nitrogen dioxide (NOz), which is toxic at low levels. OSHA has set exposure limits for NOz at 5 ppm. Animal studies have shown altered surfactant hysteresis and produced alveolar cell hyperplasia, changes in the epithelium of the terminal bronchiole, and loss of cilia at inhaled NOZ concentrations as low as 2 ppm (Evans et al., 1972, Arch. Environ. Health 24:180;
Stephens et al., 1972, Arch. Environ. Health 24:160. In humans, 2.3 ppm NOZ has been shown to affect alveolar permeability (Rasmussen et al., 1992, Am. Rev. Respir.
Dis. 146:654). Increased airway reactivity in humans has been found at inhaled NO2 concentrations below 2 ppm (Bylin et al., 1988, Eur. Respir. J. 1:606; Morrow et al., 1992, Am. Rev. Respir. Dis. 145:291; Stephens et al . , supra) .
NO is typically manufactured from the reaction of sulfur dioxide with nitric acid (Body et al., 1995, J.
Cardiothorac. Vasc. Anesth. 9:748). Alternatively, it can be produced by reacting sodium nitrite and sulfuric acid (Young et al., 1996, Intensive Care Med. 22:77) or by the oxidation of ammonia over a platinum catalyst at high temperatures (Body et al., supra). Following its production, NO is mixed with nitrogen gas (NZ) to obtain the desired NO concentration. The NO/NZ mixture is placed into specially prepared, aluminum alloy cylinders. For medical applications, cylinders typically contain 400 to WO 99Id9921 PCT/US99/07183 800 ppm NO (Hess et al., supra). In an NO cylinder, the N02 concentration is normally less than 2~ of the NO
concentration-.
Summary of the Invention The invention features a device for pulsed delivery of inhaled nitric oxide to a spontaneously breathing patient. The device includes a valve having a first, a second, and a third port. The first port is selectively communicable with the second port or the third port. The device also includes a pressure sensor in fluid communication with the third port. A valve controller is responsive to the pressure sensor. The valve controller selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined pulse time. A monitor operably linked to the valve controller measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time, and then signals the valve controller to reconnect the first port to the third port. The monitor and automatic purge cycle advantageously protect the patient from exposure to NOZ
Which otherwise would accumulate in fluid lines during an extended period in which NO/nitrogen does not flow.
The device can include a means for inactivation when not in use, e.g., an on/off switch, and a means for triggering the valve controller to selectively connect the first port to the second port for a predetermined purge time whenever the device undergoes start-up following a state of inactivation. This feature advantageously protects the patient from exposure to NOz accumulated in the fluid lines, when the patient initiates use of the device after the device has been turned off.
The purge time is preselected to provide a purge volume of 1 to 5 dead space volumes, preferably from 2 to 4 dead space volumes, and most preferably about 3 dead space volumes.
The device can also include an alarm operably connected to the monitor. The alarm provides a visual or audible indication whenever the duration of connection between the first port and third port exceeds a predetermined flow-off time, i.e., when the pressure sensor fails to detect inspiration by the patient. The alarm alerts the patient and/or a caretaker that pulsatile delivery of NO has not occurred for a preselected time, e.g., 15 seconds, 30 seconds, or 45 seconds.
The device can also include a purge cycle indicator that provides a continuous visual or audible indication that begins whenever a purge cycle begins, continues throughout the purge cycle, and ends when the purge cycle ends. This indicator warns the patient or caretaker when to wait for NOZ to be purged from the system, and when it is safe to begin use of the device.
The invention also includes a dual delivery device for separate, concurrent, pulsed delivery of inhaled nitric oxide and pulsed delivery of oxygen through a split nasal cannula to a spontaneously breathing patient.
NO is delivered through one side of the split cannula, and oxygen is delivered independently through the other side of the split cannula.
The NO portion of the dual delivery device includes a valve having a first, a second, and a third port. The first port is selectively communicable with the second port or the third port. The NO portion of the device also includes a pressure sensor in fluid communication with the third port, and a valve controller responsive to the pressure sensor. The valve controller selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined NO pulse time. A
monitor operably linked to the valve controller measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time. The monitor then signals the valve controller to reconnect the first port to the third port.
The dual delivery device also includes a pulsed oxygen delivery system that includes a valve having a first, a second, and a third port. The first port is selectively communicable with the second port or the third port. The oxygen portion of the dual delivery device also includes a pressure sensor in fluid communication with the third port, and a valve controller responsive to the pressure sensor. The valve controller selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined oxygen pulse time.
The oxygen portion of the dual delivery device can also include a monitor operably linked to the valve controller. The monitor measures the duration of WO 99Ia9921 PCT/US99/07183 connection between the first port and third port; and an alarm indicator operably linked to the monitor so that an oxygen pulse "fail" alarm indication results when the monitor detects a duration of connection between the first port and third port equal to, or greater than a predetermined time limit. This feature alerts the patient or caregiver that the desired pulsed oxygen delivery is not taking place on the oxygen side of the system.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present application, including definitions will control. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference.
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
Brief Description of the DrawincLs FIG. 1 is a block diagram showing the arrangement of a valve, valve controller, pressure sensor, monitor, and alarm, in a device according to the invention.
FIG. 2 is a schematic diagram of a purge timing circuit useful in a device according to the invention.
WO 99149921 PCTlUS99/07183 FIG. 3 is a schematic diagram of purge delay circuitry useful in a device according to the invention.
FIG. 4 is a schematic diagram of alarm circuitry useful in a'device according to the invention.
FIG. 5 is a schematic representation of a device for separate, concurrent, pulsed delivery of inhaled NO
through a split cannula system to a spontaneously breathing patient.
Detailed Description An embodiment of the invention represented schematically in FIG. 1 includes a three-way, two position valve 10, such as a solenoid-actuated, spool valve. Valve 10 has ports 10a, lOb, and lOc in its bore.
Port 10a is connected to a line (not shown) so as to be in fluid communication with a nasal cannula (not shown).
Port lOc is connected to a line (not shown) so as to be in fluid communication with a source of NO gas (not shown). Port lOb is in fluid communication with a pressure sensor 20 by means of fluid line 15. The position of the valve 10 is electrically controlled by a valve controller 30.
When a patient wearing the nasal cannula inhales during normal breathing, gas pressure in the cannula drops below ambient air pressure. This negative pressure is transmitted from port 10a through the valve and through fluid line 15 to the pressure sensor 20. Upon sensing a negative pressure event, the pressure sensor 20 causes the valve controller 30 to selectively connect port l0a to port lOc. In this "flow-on" position, the valve 10 allows NO gas to flow into the nasal cannula, from which the NO gas is delivered into one, or both, of the patient's nostrils.
The valve controller 30 maintains the valve in the "flow-on" position for a predetermined "pulse" time. At _ g _ the end of the pulse time, the valve controller 30 returns the valve to the "flow-off" position (port IOa connected to port lOb), thereby completing a pulsed dose cycle. With the valve returned to the "flow-off"
position, the device is ready for detection of the patient's next breath, and repetition of the pulsed dose cycle.
The pressure sensor 20 includes suitable means for sensing a negative fluidic pressure applied along line 15 and for generating an electrical signal upon sensing a negative pressure event. Suitable means for sensing a negative pressure associated with normal breathing include a pressure-to-electric (P/E) switch, which can be used in conjunction with a fluid amplifier. In some embodiments, the pressure sensor 20 includes a pressure transducer, e.g., a solid state-type, a capacitance-type, or an diaphragm-type (electromechanical) transducer.
Suitable valves, pressure sensing devices, valve controlling devices, and their integrated use for pulsatile delivery of a gas {oxygen) to a patient are described in detail in Durkan et al., U.S. Patent No.
4,462,398. Prior art teachings with regard to devices for pulsatile delivery of oxygen through a nasal cannula are generally applicable in the present invention, except for possible material compatibility considerations.
Materials compatible with NO include Teflon~, silicone, nickel, aluminum, and stainless steel. In addition, high pressure rubber hoses and plastic tubing commonly used for oxygen delivery are suitable for use with the NO
concentrations used clinically.
The monitor 50 measures the flow-off time, i.e., the time during which port l0a of the valve 10 is connected to port lOb of the valve 10. When the valve 10 remains in the flow-off position for a predetermined time limit, the monitor 50 electrically signals the valve WO 99Jd9921 PCT/US99/07183 controller 30 to switch the valve 10 to the flow-on position (i.e., port 10a connected to port lOc) for a predetermined "purge" time. At the end of the predetermined purge time, the valve controller 30 switches the valve 10 back to the flow-off position, thus completing a purge cycle.
As long as the mixture of NO and nitrogen is flowing from the source and through the system, air is prevented from backing up into the nasal cannula. During the flow-off time, air begins mixing with residual NO in the nasal cannula. Oxygen in the air spontaneously reacts with the residual NO in the lines to produce NOZ, which is toxic. Thus, when the flow-off time reaches a predetermined limit, the monitor 50 electrically signals the valve controller 30 to switch the valve 10 to the flow-on position. This causes a predetermined amount of gaseous NO/nitrogen ("purge volume") to flow from the source (gas cylinder) and through the system, thereby purging accumulated NOZ from the valve 10, the cannula, and any lines between the valve 10 and the cannula.
Preferably, the purge volume is between 1 and 5 dead space volumes. More preferably, the purge volume is between 2 and 4 dead space volumes, with about 3 dead space volumes being most preferred. The dead space volume is the total volume in the fluid path between port lOb and the ends of the nasal prongs, which terminate the nasal cannula. The dead space volume can be calculated readily from the internal dimensions of the components of the fluid pathway. The flow rate of the gaseous mixture of NO/nitrogen will be adjustable and known in terms of volume per unit time. Using this information, the desired purge volume can be converted to the predetermined purge time incorporated in a purge cycle.
In the embodiment represented by FIG. 1, the monitor measures the flow-off time indirectly, by means WO 99/d9921 PCT/US99/07183 of electrical connections with the valve controller 30.
In other embodiments, the monitor measures the duration indirectly, by means of electrical signals from the pressure sensor 20. In yet other embodiments, the monitor measures the duration directly, by means of a connection (electrical or mechanical) with the valve 10.
In the embodiment depicted in FIG. 1, the valve controller 30 controls the position of the valve 10. The valve controller 30 provides an input to the monitor 50 that indicates whether the valve 10 is in the "flow-off"
position lOb (logical 1 or high voltage) or the "flow-on"
position lOc (logical 0 or low voltage). The monitor 50 can employ a variety of methods to control the valve controller 30 and the alarm 40. These methods include microprocessor circuitry or TTL compatible circuitry. As an example, a monitor 50 that employs a combination of FETs and analog devices is described.
Referring to FIG. 2, a purge timing circuit has an input Vin that represents the flow-off and flow-on positions of the valve 10. When the valve is in the flow-off position, Vin transitions to a high voltage.
Previous to the transition, the P-channel FETs (Q2, Q3, and Q5) were conductive, i.e., on, and the N-channel FET
Q1 was not conductive, i.e., off. When the valve position changes and Vin transitions from a low to a high voltage, the P-channel FETs are turned off and the N-channel FET Q1 is turned on. Thus, the circuit is no longer clamped to ground. Current begins to flow from Vdd through Q1 and through the RC circuit formed by R1 and C1. After a time delay defined by the RC time constant, the voltage at the gate of Q4 is sufficient to turn Q4 on. At this time, current flows from Vdd through Q4 and Vpurge goes high.
When V purge is high, the valve controller 30 changes the position of the valve 10 to the flow-on position and purges the system. Consequently, the value of Vin transitions back to "0". The P-channel FETs Q2, Q3 and Q5 are on and the N-channel FET Q1 is off.
Because the circuit is clamped to ground, the N-channel FET Q4 also is off and Vpurge returns to a "0".
The parameters of the purge timing circuitry are chosen to produce a transition at Vpurge after a predetermined time delay. For example, vdd is 5 V; the threshold voltages of Q1, Q2, Q3, and Q5 are relatively low, e.g., 1 V; the threshold voltage of Q4 is higher, e.g., 4.5 V; and the RC time constant of R1 and C1 is designed to be approximately 15 seconds. Therefore, Q4 will turn on after approximately 15 seconds because the threshold voltage is chosen to be 90~ of the supply voltage Vdd. If Vin is not high for 15 seconds or more, the P-channel FETs Q2, Q3, and Q5 reset the circuit by clamping the circuit to ground and discharging the capacitor.
Referring to the purge delay circuitry of FIG. 3, when Vpurge is high, the signal Vwait goes high and provides a signal to the valve controller that the system should purge NO in the lines. The valve 10 moves to the "flow-on" position and NO flows through the system. The valve 10 (FIG. 1) remains in the flow-on position until Vwait, a pulse of predetermined duration, transitions back to a low state. The purge is also initiated on system startup by a power-on pulse which is the second input in the three input OR gate. The power on pulse is generated only once by a trigger device, known in the prior art, and ensures that fresh NO is available at start up.
The purge delay circuitry has an RC delay formed by R2 and C2 similar to the purge timing circuitry. The RC delay is designed to extend the Vwait pulse for the period required to purge 1 to 5 dead volumes of N0.
WO 99Id9921 PCT/US99/07183 When Vpurge goes high, P-channel FETs Q7, Q8 and Q10 turn off and N-channel FET Q8 turns on. C2 begins to charge, and the drain of Q6 is connected to the gate of Q11. Therefore, N-channel FET Q9 is off; P-channel FET
Q12 is on; and the combination of Q11 and Q12 conducts current to the gate of N-channel FET Q13. Because P-channel FET Q14 is off, the voltage at Vwait transitions to Vdd. Thus, the output transitions high almost instantaneously.
Vwait is fed back into the three input OR gate and holds the input to the gates of Q6 and Q7 at a high level. Thus, when valve 10 moves to the flow-on position and Vpurge transitions back to low, Vwait will remain high, and the RC circuit will continue to charge capacitor C2. When the capacitor is charged after a period defined by the RC delay of the circuit, Q9 turns on, and the gate of Q12 is high. Thus, Q12, a P-channel FET, stops conducting and the gates of Q13 and Q14 are low. When the gates are at a low voltage, Q13 is off and Q14 clamps Vwait to ground. When the pulse Vwait terminates, the valve controller 30 changes the valve position, and the purge timing circuitry again begins to monitor for pressure changes.
Similar to the purge timing circuitry, Q6, Q7, Q8 and Q10 of the purge wait circuitry have relatively low threshold voltages, e.g., 1 V, and Q9 has a threshold voltage approximately 90~ of Vdd. Resistor R3 is a small resistor that ensures the full value of Vdd is applied to the gates of Q13 and Q14.
The monitor 50 is electrically connected to an alarm 40, which indicates when the predetermined flow-off time limit has been reached. A flow-off time in excess of the predetermined limit can result from various causes. For example, the nasal cannula may become dislodged from the patient's nostrils when the patient WO 99/d9921 PCT/US99/07183 moves his/her head while asleep. The alarm 40 includes a visual indication such as a flashing light, or an audible indication such as a beeping tone, or both. The alarm alerts the patient or caretaker(s), so that the condition causing cessation of pulsed NO delivery can be promptly corrected. Prompt correction is particularly important where an NO rebound effect is a concern. NO rebound effects include pulmonary hypertension, hypoxemia, and heart failure.
Several alarm configurations can be constructed from the circuitry in FIGS. 2-4. For example, the output Vpurge can be connected to a "Wait" light (FIG. 5) to indicate the system is purging. The complement of Vwait can be connected to a "Ready" light to indicate the system has completed purging. Referring to FIG. 4, the reset logic is used for an embodiment of the invention where the patient, or other person, must reset a "Fail"
(FIG. 5) light when a purge is performed. The output Vpurge is the input into an OR gate OR-1. The output of OR-1 is fed back as the second input to maintain the output Vfail in a high state. Vfail is connected to a "Fail" light (not shown) which is illuminated when Vfail is high. N-channel FET Q16 resets OR-1 when AND-1 provides a low output to the gate of Q16. With Vpurge low, Q16 causes the second input to OR-1 to go low, causing Vfail to go low.
However, Vfail does not transition to the low state until the purge cycle is complete (Vwait is low) and the patient resets the fail light (Reset = on).
These signals are ANDed in AND-1 to detect this state.
The output of AND-1 is used to reset the feedback of OR-1 and OR-2.
Because Vpurge will transition to a low state before Vwait, Vfail will transition low when the feed back loop is clamped to ground.
OR-2 has a feedback loop to ensure that, if the fail reset is pressed before the purge cycle is complete, the fail light will extinguish when Vwait transitions to a low state. With AND-1 at a low state, N-channel FET
Q15 will be off, which keeps OR-2 high. AND-1 will remain at a logic low state until Vwait goes low. When AND-1 goes high, the OR-2 and OR-1 gates are reset. The resistors R4 and R5 are small resistors that prevent the clamping FETs Q15 and Q16 from shorting Vdd to ground and that ensure the input is clamped to ground quickly. The circuitry does not generate a fail light on start up when the system initially purges, but does generate a wait light on start up based on Vwait.
Preferred embodiments of the invention include a purge cycle indicator, which is activated at the beginning of every purge cycle and deactivated at the end of the purge cycle. The indicator can be visual, audible, or both. The purge indicator can be a readily visible, color-coded light or a liquid crystal display.
Suitable markings for a light that illuminates during the purge cycle include "WAIT" and "PURGING." Suitable purge-cycle messages for a liquid crystal display include "WAIT" and "PURGING." Upon completion of the purge cycle, suitable liquid crystal display messages include "OK" and "READY."
Preferred embodiments of the invention include automatic purging each time the device is connected to a power source after having been disconnected. Connection and disconnection can be by means of an ordinary on/off switch, by battery insertion and removal, or by plugging and unplugging a power cord. Preferably, a purge cycle (discussed above) is triggered whenever an electrical circuit in the valve controller 30 energized after having been de-energized.
Typically, the source of gaseous NO/nitrogen used for inhaled NO therapy is a high pressure cylinder, which requires an appropriate (pin index safety system or diameter index safety system) pressure regulator. A
device according to this invention can be incorporated into an integrated unit that includes a pressure regulator. Alternatively, the device can be a separate unit connected between a conventional NO pressure regulator and a conventional nasal cannula.
The device of this invention can be used in conjunction with a conventional flow regulator.
Referring to Fig. 1, the flow regulator (not shown) is inserted at a point in the fluid path between a pressure regulator (not shown) and port 10c on the valve 10.
Referring to Fig. 1, the NO dosage delivered to the patient by the device of this invention can be adjusted in any of at least three ways. One way of adjusting the dosage is varying the pulse time, i.e., the time that the valve 10 is in the flow-on position during a pulsed dose cycle, wherein the flow rate remains constant. A second way of adjusting the dosage is varying NO/nitrogen flow rate, wherein the pulse time remains constant. Flow rate can be adjusted by any suitable means, e.g., a manual valve or a proportioning solenoid. A third way of adjusting the dosage is programming the valve controller 30 to move the valve 10 to the flow-on position on a breath-dependent schedule, e.g., every second breath, every third breath, or every fourth breath.
In therapeutic use of a device of this invention, the desired NO dosage will be determined in accordance with accepted medical practice, depending on the condition being treated and the status of the patient.
Regardless of the means for adjusting NO dosage, the NO/nitrogen flow rate during the flow-on phase of the WO 99Id9921 PCT/US99/07183 pulsed dose cycle is preferably from 0.25 to 8 liters per minute, and more preferably from 1 to 4 liters per minute.
The following equations are useful for obtaining the desired NO dosage when delivering inhaled NO through a nasal cannula system:
[N03 - (NO flow x source ppm) /total flow [NO] in cannula = (desired NO dose x mean inspiratory flow)/cannula flow For additional guidance concerning calculations and considerations for inhaled NO delivery systems, see Hess et al., 1997, Resp. Care Clinics of North America 3:371.
FIG. 5 illustrates selected features of a device 60 for separate, concurrent, pulsed delivery of inhaled nitric oxide and pulsed delivery of oxygen through a split nasal cannula 80, 81. to a spontaneously breathing patient.
A mixture of NO/nitric oxide flows from an NO
source cylinder 68 through a cylinder shutoff valve 65, a pressure regulator 66, and fluid line 69, into the device 60. The NO control panel 60a includes an NO main power switch 67 and a knob 61 for adjusting NO dosage to the desired level. The NO control panel 60a also includes a purge cycle indicator light 64, an indicator light that signals when it is safe for the patient to begin using the device 63, and an alarm indicator light 62.
Oxygen flows from an oxygen source cylinder 78 through a cylinder shutoff valve 75, a pressure regulator 76, and fluid line 79, into the device 60. The oxygen control panel 60b includes an oxygen main power switch 77 and a knob 71 for adjusting oxygen dosage to the desired level. The oxygen control panel 60b includes a first light 73, which indicates that pulsed oxygen delivery is proceeding without the oxygen flow-off time exceeding the predetermined limit. The oxygen control panel 60b also includes a second light 72, which indicates that pulsed WO 99149921 . PCT/US99/07183 oxygen delivery has failed to occur without exceeding the predetermined flow-off time.
Other embodiments are within the following claims.
Claims (8)
1. A device for pulsed delivery of inhaled nitric oxide to a spontaneously breathing patient, comprising:
a hardware fitting specific for a nitric oxide pressure regulator or a high pressure nitric oxide cylinder;
a valve having a first, a second, and a third port, the first port being selectively communicable with the second port or the third port;
a pressure sensor in fluid communication with the third port;
a valve controller which is responsive to the pressure sensor, and which selectively connects the first port to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined pulse time; and a monitor which is operably linked to the valve controller, and which measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time, and then signals the valve controller to reconnect the first port to the third port.
a hardware fitting specific for a nitric oxide pressure regulator or a high pressure nitric oxide cylinder;
a valve having a first, a second, and a third port, the first port being selectively communicable with the second port or the third port;
a pressure sensor in fluid communication with the third port;
a valve controller which is responsive to the pressure sensor, and which selectively connects the first port to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined pulse time; and a monitor which is operably linked to the valve controller, and which measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time, and then signals the valve controller to reconnect the first port to the third port.
2. The device of claim 1, further comprising a means for inactivating the device when not in use, and a means for triggering the valve controller to selectively connect the first port to the second port for a predetermined purge time whenever the device undergoes start-up following a state of inactivation.
3. The device of claim 1, wherein the purge time is preselected so as to provide a purge volume of 1 to 5 dead space volumes.
4. The device of claim 3, wherein the purge volume is from 2 to 4 dead space volumes.
5. The device of claim 1, further comprising an alarm which is operably connected to the monitor, and which provides a visual or audible indication whenever the duration of connection between the first port and third port exceeds a predetermined flow-off time.
6. The device of claim 1, further comprising a purge cycle indicator that provides a continuous visual or audible indication that begins whenever a purge cycle begins, continues throughout the purge cycle, and ends when the purge cycle ends.
7. A device for separate, concurrent, pulsed delivery of inhaled nitric oxide and pulsed delivery of oxygen through a split nasal cannula to a spontaneously breathing patient, comprising:
a hardware fitting specific for a nitric oxide pressure regulator or a high pressure nitric oxide cylinder;
a pulsed nitric oxide delivery system comprising:
a valve having a first, a second, and a third port, the first port being selectively communicable with the second port or the third port;
a pressure sensor in fluid communication with the third port;
a valve controller which is responsive to the pressure sensor, and which selectively connects the first port to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined nitric oxide pulse time; and a monitor which is operably linked to the valve controller, and which measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time, and then signals the valve controller to reconnect the first port to the third port; and a pulsed oxygen delivery system comprising:
a valve having a first, a second, and a third port, the first port being selectively communicable with the second port or the third port;
a pressure sensor in fluid communication with the third port; and a valve controller which is responsive to the pressure sensor, and which selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined oxygen pulse time.
a hardware fitting specific for a nitric oxide pressure regulator or a high pressure nitric oxide cylinder;
a pulsed nitric oxide delivery system comprising:
a valve having a first, a second, and a third port, the first port being selectively communicable with the second port or the third port;
a pressure sensor in fluid communication with the third port;
a valve controller which is responsive to the pressure sensor, and which selectively connects the first port to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined nitric oxide pulse time; and a monitor which is operably linked to the valve controller, and which measures the duration of connection between the first port and third port, and signals the valve controller to selectively connect the first port to the second port for a predetermined purge time when the duration of connection between the first port and third port exceeds a predetermined flow-off time, and then signals the valve controller to reconnect the first port to the third port; and a pulsed oxygen delivery system comprising:
a valve having a first, a second, and a third port, the first port being selectively communicable with the second port or the third port;
a pressure sensor in fluid communication with the third port; and a valve controller which is responsive to the pressure sensor, and which selectively connects the first port to the to the second port when a negative pressure event is sensed, maintains the connection for at least a portion of the negative pressure event duration, and reconnects the first port to the third port after a predetermined oxygen pulse time.
8. The device of claim 7, further comprising an alarm system comprising:
a monitor operably linked to the valve controller, which monitor measures the duration of connection between the first port and third port; and an alarm indicator operably linked to the monitor so that an alarm indication results when the monitor detects a duration of connection between the first port and third port equal to, or greater than a predetermined time limit.
a monitor operably linked to the valve controller, which monitor measures the duration of connection between the first port and third port; and an alarm indicator operably linked to the monitor so that an alarm indication results when the monitor detects a duration of connection between the first port and third port equal to, or greater than a predetermined time limit.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8004898P | 1998-03-31 | 1998-03-31 | |
| US60/080,048 | 1998-03-31 | ||
| US09/064,123 US6142147A (en) | 1998-03-31 | 1998-04-21 | Nasal delivery system for inhaled nitric oxide |
| US09/064,123 | 1998-04-21 | ||
| PCT/US1999/007183 WO1999049921A1 (en) | 1998-03-31 | 1999-03-31 | Nasal delivery system for inhaled nitric oxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2326552A1 true CA2326552A1 (en) | 1999-10-07 |
Family
ID=26744174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002326552A Abandoned CA2326552A1 (en) | 1998-03-31 | 1999-03-31 | Nasal delivery system for inhaled nitric oxide |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6142147A (en) |
| EP (1) | EP1067978A1 (en) |
| AU (1) | AU3462499A (en) |
| CA (1) | CA2326552A1 (en) |
| WO (1) | WO1999049921A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108355215A (en) * | 2012-12-04 | 2018-08-03 | 马林克罗特医疗产品知识产权公司 | Casing for being minimized to the dilution of administration during nitrogen oxide delivers |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6089229A (en) * | 1998-05-26 | 2000-07-18 | Datex-Ohmeda, Inc. | High concentration no pulse delivery device |
| US6538249B1 (en) * | 1999-07-09 | 2003-03-25 | Hitachi, Ltd. | Image-formation apparatus using charged particle beams under various focus conditions |
| DE60043731D1 (en) * | 1999-08-02 | 2010-03-11 | Univ Duke | METHOD FOR DETERMINING THE PHYSIOLOGICAL EFFECTS OF HEMOGLOBIN |
| US6694969B1 (en) * | 1999-09-22 | 2004-02-24 | Instrumentarium Corp. | Method to improve oxygenation in subjects suffering impaired oxygenation |
| US7516742B2 (en) | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
| US6581599B1 (en) * | 1999-11-24 | 2003-06-24 | Sensormedics Corporation | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients |
| DE19960404A1 (en) * | 1999-12-15 | 2001-07-05 | Messer Austria Gmbh Gumpoldski | Expiration-dependent gas metering |
| US6668828B1 (en) | 2000-10-16 | 2003-12-30 | Pulmonox Technologies Corporations | System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient |
| US20050004511A1 (en) * | 2000-10-16 | 2005-01-06 | Curtis Figley | Method for purging a system for use in administrating therapeutic gas to a patient |
| US7335181B2 (en) * | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
| US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
| US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| US6725860B2 (en) * | 2001-02-07 | 2004-04-27 | DRäGER MEDIZINTECHNIK GMBH | Monitoring process for metering different gaseous anesthetics |
| US6749834B2 (en) * | 2001-06-19 | 2004-06-15 | World Precision Instruments, Inc. | Methods and apparatus for therapeutic treatment of respiratory, cardiac and other pathologies |
| US7387123B2 (en) * | 2001-11-30 | 2008-06-17 | Viasys Manufacturing, Inc. | Gas identification system and volumetrically correct gas delivery system |
| US6920876B2 (en) * | 2001-12-10 | 2005-07-26 | Pulmonox Technologies Corporation | Device for administration of nitric oxide to horses spontaneously breathing |
| GB0207422D0 (en) * | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
| US7531133B2 (en) | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
| US6976490B2 (en) * | 2002-12-10 | 2005-12-20 | Essex Manufacturing Company | Therapeutic single dose gas administration system |
| US9138707B2 (en) | 2002-12-10 | 2015-09-22 | Sy Kimball | Portable, nitric oxide generator |
| DE10306766A1 (en) * | 2003-02-18 | 2004-08-26 | Ino Therapeutics Gmbh | Dosed delivery of a therapeutic gas |
| CA2443510C (en) * | 2003-09-30 | 2010-09-14 | Scott Technologies, Inc. | Automatic transfer regulator for hose-line respirator |
| AU2005244078A1 (en) * | 2004-05-11 | 2005-11-24 | Pulmonox Technologies Corporation | Intermittent dosing of nitric oxide gas |
| US8518457B2 (en) | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
| JP4526313B2 (en) * | 2004-07-01 | 2010-08-18 | オリンパス株式会社 | Air supply system |
| US9358150B2 (en) * | 2005-05-13 | 2016-06-07 | Benechill, Inc. | Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance |
| US8079998B2 (en) | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
| US8789524B2 (en) * | 2008-01-22 | 2014-07-29 | General Electric Company | Pulse width modulated medical gas concentration control |
| US8720436B2 (en) * | 2008-01-31 | 2014-05-13 | Genosys, Inc. | Nitric oxide gel apparatus and method |
| US8434475B2 (en) | 2008-01-31 | 2013-05-07 | Genosys, Inc. | Nitric oxide reactor and distributor apparatus and method |
| US9649467B2 (en) | 2008-01-31 | 2017-05-16 | Syk Technologies, Llc | Nitric oxide reactor and distributor apparatus and method |
| US8501090B2 (en) * | 2008-03-24 | 2013-08-06 | Christian S. Minton | Anti-microbial gas apparatus and method |
| US8425428B2 (en) | 2008-03-31 | 2013-04-23 | Covidien Lp | Nitric oxide measurements in patients using flowfeedback |
| US10960168B2 (en) * | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
| US8652064B2 (en) | 2008-09-30 | 2014-02-18 | Covidien Lp | Sampling circuit for measuring analytes |
| CA2671029A1 (en) | 2009-06-30 | 2010-12-30 | James S. Baldassarre | Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
| CA2781295C (en) * | 2009-11-20 | 2018-02-13 | Geno Llc | Nitric oxide delivery system |
| US20110139163A1 (en) * | 2009-12-15 | 2011-06-16 | Hillila David J | Vibration apparatus for stimulating paranasal sinuses |
| US8726900B1 (en) * | 2010-02-01 | 2014-05-20 | Ramses Nashed | Demand anesthetic gas delivery system with disposable breathing and scavenging circuit |
| US8685467B2 (en) | 2010-08-03 | 2014-04-01 | J. W. Randolph Miller | Nitric oxide generation, dilution, and topical application apparatus and method |
| BR112013020994A2 (en) * | 2011-02-21 | 2018-07-10 | Koninklijke Philips Nv | method for generating a gas flow and assembling to provide a gas flow |
| CN104411317A (en) * | 2012-03-15 | 2015-03-11 | Ino治疗有限责任公司 | Methods of administering high concentrations of nitric oxide |
| US8944051B2 (en) | 2012-04-05 | 2015-02-03 | Ino Therapeutics Llc | Breathing apparatus detection and purging |
| US20130273180A1 (en) * | 2012-04-16 | 2013-10-17 | Denise Barbut | System and method for improving outcome of cerebral ischemia |
| US9795756B2 (en) | 2012-12-04 | 2017-10-24 | Mallinckrodt Hospital Products IP Limited | Cannula for minimizing dilution of dosing during nitric oxide delivery |
| US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
| US9486600B2 (en) | 2013-06-28 | 2016-11-08 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Nasal cannula assembly with inhalation valves communicating with a deformable reservoir |
| US9566407B2 (en) | 2013-06-28 | 2017-02-14 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Nasal cannula assembly with flow control passage communicating with a deformable reservoir |
| US9517318B2 (en) | 2013-06-28 | 2016-12-13 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Method of delivering medical gases via a nasal cannula assembly with flow control passage communicating with a deformable reservoir |
| US9522247B2 (en) | 2013-06-28 | 2016-12-20 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Method of treating a patient having pulmonary hypertension by long term NO therapy |
| US9522248B2 (en) | 2013-06-28 | 2016-12-20 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Breathing assistance apparatus for delivery of nitric oxide to a patient by means of a nasal cannula assembly with flow control passage |
| US9492626B2 (en) | 2013-06-28 | 2016-11-15 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Breathing assistance assemblies suitable for long term no therapy |
| FR3015000B1 (en) * | 2013-12-12 | 2016-05-27 | Air Liquide Sante (International) | SYSTEM FOR STORING AND DISPENSING NO / NITROGEN MIXTURES |
| US20160121071A1 (en) * | 2014-10-30 | 2016-05-05 | Nu-Med Plus | Controlled delivery of medical gases using diffusion membranes |
| CA3000210A1 (en) | 2015-10-01 | 2017-04-06 | Mallinckrodt Hospital Products IP Limited | Device and method for diffusing high concentration no with inhalation therapy gas |
| US10052348B2 (en) | 2016-01-27 | 2018-08-21 | Syk Technologies, Llc | Nitric oxide topical application apparatus and methods |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3653401A (en) * | 1969-10-24 | 1972-04-04 | Chemetron Corp | Utility outlet fixture with slack take-up |
| US3970103A (en) * | 1972-06-21 | 1976-07-20 | Oxequip Health Industries Inc. | Retractable gas line connecting apparatus |
| US3965903A (en) * | 1975-05-23 | 1976-06-29 | Chemetron Corporation | Suction bottle assembly |
| US4484578A (en) * | 1980-11-26 | 1984-11-27 | Kircaldie, Randall And Mcnab | Respirator apparatus and method |
| US4457303A (en) * | 1980-11-26 | 1984-07-03 | Tritec Industries, Inc. | Respirating gas supply control method and apparatus therefor |
| US4420013A (en) * | 1981-11-12 | 1983-12-13 | Cedious, Incorporated | Regulator guard |
| US4506666A (en) * | 1982-12-03 | 1985-03-26 | Kircaldie, Randall And Mcnab | Method and apparatus for rectifying obstructive apnea |
| US4527587A (en) * | 1983-03-28 | 1985-07-09 | Union Carbide Canada Limited | Connector assembly for a gas |
| US4886055A (en) * | 1988-01-22 | 1989-12-12 | Hoppough John M | Nebulizer device |
| US4991820A (en) * | 1990-02-09 | 1991-02-12 | Allied Healthcare Products, Inc. | Fluid conduit coupler |
| DE69133575T2 (en) * | 1990-12-05 | 2008-04-17 | The General Hospital Corp., Boston | Use of NO for the treatment of persistent pulmonary hypertension of the newborn |
| FR2695831B1 (en) * | 1992-09-24 | 1994-11-10 | Air Liquide | Installation and method for supplying a gaseous mixture to the respiratory tract of a user. |
| EP0621051B1 (en) * | 1993-04-17 | 2001-08-22 | MESSER GRIESHEIM AUSTRIA Ges.m.b.H. | Apparatus for the controlled dosage of NO to a patient's air supply |
| GB2279014B (en) * | 1993-06-02 | 1997-07-16 | Niall Keaney | Device for controlling delivery of respiratory drugs |
| SE9302477L (en) * | 1993-07-22 | 1995-01-23 | Siemens Elema Ab | Breathing gas supply apparatus |
| GB9320978D0 (en) * | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
| US5558083A (en) * | 1993-11-22 | 1996-09-24 | Ohmeda Inc. | Nitric oxide delivery system |
| US5485833A (en) * | 1994-06-10 | 1996-01-23 | Dietz; Henry G. | Breath exposure synchronizer |
| US5615669A (en) * | 1994-07-22 | 1997-04-01 | Siemens Elema Ab | Gas mixture and device for delivering the gas mixture to the lungs of a respiratory subject |
| ES2190467T3 (en) * | 1996-02-27 | 2003-08-01 | Koster Henk W | BREATHING SYSTEM WITH AN ADDITIONAL GAS ADMINISTRATION MODULE. |
| US5732694A (en) * | 1996-12-13 | 1998-03-31 | Ohmeda Inc. | System for correcting NO2 monitor |
| SE9602959L (en) * | 1996-08-12 | 1998-02-09 | Siemens Elema Ab | Process for mixing gases and a device for mixing gases |
| US5752506A (en) * | 1996-08-21 | 1998-05-19 | Bunnell Incorporated | Ventilator system |
| US5701883A (en) * | 1996-09-03 | 1997-12-30 | Respironics, Inc. | Oxygen mixing in a blower-based ventilator |
| US5732693A (en) * | 1996-10-02 | 1998-03-31 | Ohmeda Inc. | Pause control of nitric oxide therapy |
| US5918596A (en) * | 1997-04-22 | 1999-07-06 | Instrumentarium Corp. | Special gas dose delivery apparatus for respiration equipment |
| US6016801A (en) * | 1997-09-03 | 2000-01-25 | Philips; Monir Wasef | Nitrous oxide delivery system |
-
1998
- 1998-04-21 US US09/064,123 patent/US6142147A/en not_active Expired - Fee Related
-
1999
- 1999-03-31 WO PCT/US1999/007183 patent/WO1999049921A1/en not_active Application Discontinuation
- 1999-03-31 AU AU34624/99A patent/AU3462499A/en not_active Abandoned
- 1999-03-31 EP EP99916269A patent/EP1067978A1/en not_active Withdrawn
- 1999-03-31 CA CA002326552A patent/CA2326552A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108355215A (en) * | 2012-12-04 | 2018-08-03 | 马林克罗特医疗产品知识产权公司 | Casing for being minimized to the dilution of administration during nitrogen oxide delivers |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1067978A1 (en) | 2001-01-17 |
| AU3462499A (en) | 1999-10-18 |
| US6142147A (en) | 2000-11-07 |
| WO1999049921A1 (en) | 1999-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6142147A (en) | Nasal delivery system for inhaled nitric oxide | |
| US7955294B2 (en) | Intermittent dosing of nitric oxide gas | |
| JP5470264B2 (en) | Patient interface assembly for respiratory therapy | |
| JP4938804B2 (en) | Hardware configuration for pressure driver | |
| CA2836041C (en) | System and method of administering a pharmaceutical gas to a patient | |
| ES2245076T3 (en) | DEVICE FOR SUPPLY FOR PULSES FROM NO TO HIGH CONCENTRATIONS. | |
| US5839433A (en) | Nitric oxide treatment | |
| US11827989B2 (en) | Systems and methods for preventing and treating infections with nitric oxide | |
| JP2001525717A (en) | Tracheal ventilation delivery system for breathing apparatus | |
| ES2232916T3 (en) | SUPPLY DEVICE FOR NITRIC OXIDE IMPULSES TO CONSTANT VOLUME. | |
| JPH06197968A (en) | Medical oxygen supplier | |
| EP2269676A2 (en) | Apparatus for the administration of continuous positive airway pressure therapy | |
| CN116157182A (en) | Flow triggered gas delivery | |
| AU2014201260B2 (en) | System and method of administering a pharmaceutical gas to a patient | |
| AU2015201474B2 (en) | System and method of administering a pharmaceutical gas to a patient | |
| JPH06205833A (en) | Inspiratory gas supply device | |
| JP2000300674A (en) | Oxygen and nitrogen monoxide supply apparatus | |
| US20170304580A1 (en) | Device for ventilating a patient and method for operating a device for ventilating a patient | |
| AU2018229527A1 (en) | System and method of administering a pharmaceutical gas to a patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |